The International Drug Development Institute (IDDI) has announced changes to its executive leadership team to strengthen the company’s leadership and operational capabilities.

David Loose has been appointed as chief executive officer of Essex Management, part of contract research organisation Emmes Group.

Vect-Horus, a private biotechnology company specialising in molecular development, has announced the appointment of Jérôme Berger to its board of directors.

PrecisionLife has appointed seasoned executive Bill Keating as chief commercial officer of Diagnostics and Healthcare to drive commercial strategy for precision medicine.

Novel obesity treatment-focused biopharmaceutical company Antag Therapeutics has announced the appointment of Joerg Moeller MD PhD as chief executive officer.

Exevir Bio, a biotech company focused on developing heavy chain-only antibodies to target highly conserved epitopes for broad-spectrum protection against infectious diseases, has announced the appointment of Michael Garrett as its new CEO.

Biosynth – known for supplying the life sciences industry with critical raw materials and services – has announced that Matt Gunnison has been appointed as its new CEO and Kieran Murphy has been appointed as chairman.

Following the stepping down of the previous chair, Gerd Zettlmeissl, MinervaX has appointed Veronica Gambillara Fonck to lead the board of directors.

Pharma Tech Industries, a pharmaceutical manufacturing and packaging solutions contractor for wellness products and medical devices, has announced the appointment of its new chief executive officer, Darrin T Schellin.

Cluepoints, a data quality oversight and and risk-based quality management software provider, has announced the appointment of Richard Young as its chief strategy officer.

Dr Souad Kechairi has been appointed chief medical officer at PLL Therapeutics, a biopharmaceutical company specialising in polypeptides.

Pacira biosciences, specialist in non-opioid pain therapies, has appointed Shawn Cross as its chief financial officer. In this role, Mr Cross will take over all responsibility for the company’s financial operations.